Comparison between a single dose of goserelin (depot) and multiple daily doses of leuprolide acetate for pituitary suppression in IVF treatment: a clinical endocrinological study of the ovarian response.
OBJECTIVE
Compare the efficacy and safety of two different GnRHa, used for pituitary suppression in IVF cycles.


METHODS
A total of 292 patients using depot goserelin (Group 1) and 167 using daily leuprolide acetate (Group 2) were compared. Days required to achieve pituitary function suppression, duration of ovarian stimulation, total dose of HMG, number of aspirated follicles, number of oocytes retrieved, and presence of functional ovarian cyst were analyzed.


RESULTS
The time taken to achieve downregulation was similar. The mean number of ampoules used for superovulation was higher in Group 1; however, this difference was observed only for patients >40 years old that started GnRHa in the follicular phase. There was no difference between the two groups in the duration of superovulation, in the number of follicles aspirated, and the number of oocytes retrieved. In the group of patients with >40 years the incidence of ovarian cysts was higher in Group 2.


CONCLUSIONS
Both routes of GnRHa have similar effects for pituitary suppression and ovulation induction in assisted reproductive technology. Therefore the long-acting GnRHa is an excellent option, as only a single subcutaneous dose is necessary, decreasing the risk of the patient to forget its use and, most important, it does not interfere in the patient's quality of life.
Geber
Selmo
S
ORIGEN, Centro de Medicina Reprodutiva, Belo Horizonte, Minas Gerais, Brazil. sjgeber@bhnet.com.br
Sales
Liana
L
Sampaio
Marcos A C
MA
D000328:Adult; D015536:Down-Regulation / Q000187:drug effects; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage*; D005307:Fertilization in Vitro / Q000187:drug effects*; D017273:Goserelin / Q000008:administration & dosage*; D006801:Humans; D007279:Injections, Subcutaneous; D016729:Leuprolide / Q000008:administration & dosage*; D008597:Menstrual Cycle / Q000187:drug effects; D010053:Ovary / Q000187:drug effects*; D010062:Ovulation Induction / Q000379:methods; D010902:Pituitary Gland / Q000187:drug effects* / Q000502:physiology
D005300:Fertility Agents, Female; D017273:Goserelin; D016729:Leuprolide